X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs CIPLA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB CIPLA DR. REDDYS LAB/
CIPLA
 
P/E (TTM) x 27.2 43.5 62.5% View Chart
P/BV x 2.8 3.6 78.2% View Chart
Dividend Yield % 1.0 0.4 282.2%  

Financials

 DR. REDDYS LAB   CIPLA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-16
CIPLA
Mar-17
DR. REDDYS LAB/
CIPLA
5-Yr Chart
Click to enlarge
High Rs4,383622 704.8%   
Low Rs2,750458 600.0%   
Sales per share (Unadj.) Rs920.1181.9 506.0%  
Earnings per share (Unadj.) Rs126.112.9 979.8%  
Cash flow per share (Unadj.) Rs183.029.3 624.2%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %0.60.4 151.4%  
Book value per share (Unadj.) Rs685.8155.7 440.5%  
Shares outstanding (eoy) m170.61804.51 21.2%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x3.93.0 130.5%   
Avg P/E ratio x28.342.0 67.4%  
P/CF ratio (eoy) x19.518.4 105.8%  
Price / Book Value ratio x5.23.5 149.9%  
Dividend payout %15.915.5 102.1%   
Avg Mkt Cap Rs m608,481434,516 140.0%   
No. of employees `00021.723.0 94.0%   
Total wages/salary Rs m31,87426,338 121.0%   
Avg. sales/employee Rs Th7,244.46,349.1 114.1%   
Avg. wages/employee Rs Th1,470.91,143.0 128.7%   
Avg. net profit/employee Rs Th992.8449.3 221.0%   
INCOME DATA
Net Sales Rs m156,978146,302 107.3%  
Other income Rs m2,6932,287 117.8%   
Total revenues Rs m159,671148,589 107.5%   
Gross profit Rs m34,58724,758 139.7%  
Depreciation Rs m9,70513,229 73.4%   
Interest Rs m8241,594 51.7%   
Profit before tax Rs m26,75112,222 218.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,2371,798 291.3%   
Profit after tax Rs m21,51410,354 207.8%  
Gross profit margin %22.016.9 130.2%  
Effective tax rate %19.614.7 133.1%   
Net profit margin %13.77.1 193.6%  
BALANCE SHEET DATA
Current assets Rs m118,20187,370 135.3%   
Current liabilities Rs m68,36833,081 206.7%   
Net working cap to sales %31.737.1 85.5%  
Current ratio x1.72.6 65.5%  
Inventory Days Days6087 69.0%  
Debtors Days Days9762 155.5%  
Net fixed assets Rs m72,265111,567 64.8%   
Share capital Rs m8531,609 53.0%   
"Free" reserves Rs m111,548123,645 90.2%   
Net worth Rs m117,009125,254 93.4%   
Long term debt Rs m10,69036,454 29.3%   
Total assets Rs m200,104209,532 95.5%  
Interest coverage x33.58.7 386.1%   
Debt to equity ratio x0.10.3 31.4%  
Sales to assets ratio x0.80.7 112.4%   
Return on assets %11.25.7 195.8%  
Return on equity %18.48.3 222.4%  
Return on capital %21.68.5 254.0%  
Exports to sales %46.334.2 135.2%   
Imports to sales %9.08.3 107.3%   
Exports (fob) Rs m72,61850,050 145.1%   
Imports (cif) Rs m14,05012,203 115.1%   
Fx inflow Rs m75,40551,066 147.7%   
Fx outflow Rs m27,11517,678 153.4%   
Net fx Rs m48,29033,388 144.6%   
CASH FLOW
From Operations Rs m40,47623,824 169.9%  
From Investments Rs m-19,421-13,127 148.0%  
From Financial Activity Rs m-17,009-13,239 128.5%  
Net Cashflow Rs m4,046-2,478 -163.3%  

Share Holding

Indian Promoters % 25.5 16.0 159.4%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 5.4 12.2 44.3%  
FIIs % 35.3 23.7 148.9%  
ADR/GDR % 18.5 1.1 1,681.8%  
Free float % 15.3 26.2 58.4%  
Shareholders   75,885 161,166 47.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   PANACEA BIOTECH  BIOCON LTD  J.B.CHEMICALS  NATCO PHARMA  DIVIS LABORATORIES  

Compare DR. REDDYS LAB With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Aug 22, 2017 03:36 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS